LifeGuide

LifeGuide Hep C is surpassing HIV as a deadlier disease by Larry Buhl There was a new milestone reached last month when a new study suggested...

LifeGuide Running Into Options An NNRTI candidate seeks to keep on track to expand therapies by Chael Needle In this next-generation era of anti-HIV meds, research and development...

As part of a comprehensive project to eliminate hepatitis C (HCV) from the country, Gilead began providing free hep C regimens containing the company’s...

It happens every five years. The United Nations General Assembly convenes high-level meetings on HIV/AIDS to review progress on the epidemic and draw attention...

Gaining Momentum HIV vaccine candidates seek to make good on their early promise by Jeannie Wraight and David Miller Over the past several years, momentum for the...

Revving Up Investigational agent ABX 464 seeks to reduce HIV reservoirs by Jeannie Wraight ABX 464 is making its way through clinical trials, showing strong potential as...

Approved by the fda, telaprevir and boceprevir usher in a new era of treatment by Larry Buhl The first breakthrough treatments for liver disease to...

Code Switch The president of the Latino Commission on AIDS talks about tailoring messages to U.S. Latinos by Larry Buhl In early September in Philadelphia, NMAC (formerly...

Stopping Injustice Leading HIV scientists issue expert consensus statement on HIV criminalization by Hank Trout At the July 2018 IAS2018 conference in Amsterdam, The Netherlands, twenty of...

Coffee Talk Two studies shed light on HCV prevention & treatment by Larry Buhl A study on the long-term infectiousness of the hepatitis C virus (HCV) has...